Ontology highlight
ABSTRACT: Purpose
To improve the outcomes of patients with castration-resistant prostate cancer (CRPC), there is an urgent need for more effective therapies and approaches that individualize specific treatments for patients with CRPC. These studies compared the novel taxane cabazitaxel with the previous generation docetaxel, and aimed to determine which tumors are most likely to respond.Experimental design
Cabazitaxel and docetaxel were compared via in vitro modeling to determine the molecular mechanism, biochemical and cell biologic impact, and cell proliferation, which was further assessed ex vivo in human tumor explants. Isogenic pairs of RB knockdown and control cells were interrogated in vitro and in xenograft tumors for cabazitaxel response.Results
The data herein show
SUBMITTER: de Leeuw R
PROVIDER: S-EPMC4333741 | biostudies-literature | 2015 Feb
REPOSITORIES: biostudies-literature